Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesReimbursement/Payment PolicyBCBS Illinois Prenatal Screening Update | OpenPaye…
    Ask Trek AI about this page
    CurrentBlue Cross Blue Shield - IllinoisPolicy RPLAB014

    Prenatal Screening (Nongenetic)

    Customize your policy alerts

    Sign up for Blue Cross Blue Shield - Illinois Policy RPLAB014 alerts

    Get alerted when Policy RPLAB014 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs reimbursement criteria and coding for selected nongenetic prenatal screening services for pregnant individuals, including potentially reimbursable routine screening, fetal fibronectin testing, and nonreimbursable services, subject to applicable Plan documents and product requirements.

    Policy Summary
    PayerBlue Cross Blue Shield - Illinois
    PolicyPrenatal Screening (Nongenetic)
    Policy CodePolicy RPLAB014
    Change TypeMaterial revision
    Effective DateDecember 4, 2026
    Next Review DateN/A
    Key ActionSubmit accurate documentation and valid code combinations using HIPAA-approved code sets and applicable industry coding guidelines.
    SourceLink
    POLICY UPDATE CHANGES

    Prenatal screening guidance was reorganized so recommendations for bacteriuria, diabetes, hepatitis, HIV, thyroid disease, tuberculosis, and Zika virus are addressed in corresponding policies.

    Multiple prior prenatal screening subcriteria and associated procedure codes were removed from this policy.

    The exclusion for salivary hormone testing was clarified to state that testing salivary hormone levels to assess risk of preterm labor is not reimbursable.

    5Routine prenatal screening categories potentially reimbursable
    2

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Explicitly nonreimbursable testing categories
    24–28 weeksRepeat Rh(D) antibody testing window
    36–37 weeksGroup B streptococcal screening window
    25Procedure codes listed
    7Related payer policies

    Reimbursable Prenatal Screening Services

    Routine prenatal screening

    The following routine prenatal screening services may be reimbursable for all pregnant individuals.

    ONE or more of

    • Determine blood type, Rh(D) status, and antibody status during the first prenatal visit; repeat Rh(D) antibody testing at 24 to 28 weeks' gestation for unsensitized Rh(D)-negative individuals unless the biological father is known to be Rh(D)-negative.
    • Screen for anemia with a CBC or hemoglobin and hematocrit with mean corpuscular volume.
    • Screen for Group B streptococcal disease once per pregnancy, recommended during gestational weeks 36 to 37.
    • Perform rubella antibody testing.
    • Test for varicella immunity.

    Fetal fibronectin assay

    A fetal fibronectin assay may be reimbursable when all of the following conditions are met:

    ALL of the following

    • The individual is pregnant with a singleton or twin pregnancy.
    • The individual presents in the ambulatory setting with signs or symptoms of preterm labor.
    • A fetal fibronectin (FFN) assay is performed.

      The assay may be reimbursable under these clinical and setting conditions.

    Nonreimbursable testing

    The following testing is not reimbursable under the stated circumstances:

    Any of the following

    • The pregnancy is normal and without complications, and human chorionic gonadotropin (hCG) hormone testing is performed.
    • Salivary hormone levels are tested to assess risk of preterm labor.

    Codes and Billing Parameters

    Routine prenatal screening and related laboratory servicesmixedCovered
    80055Obstetric panel
    80081Obstetric panel
    85004Automated differential white blood cell count
    85007Blood smear with differential white blood cell count
    85009Manual differential white blood cell count, buffy coat
    85014Hematocrit
    85018Hemoglobin
    85025Complete CBC with automated differential white blood cell count
    85027Complete automated CBC
    85032Manual cell count, each
    1–10 of 20
    1/2
    Fetal fibronectin testingCPTCovered
    82731Assay of fetal fibronectin
    hCG testing in uncomplicated normal pregnancyCPTNot Covered
    84702Chorionic gonadotropin test
    84703Chorionic gonadotropin assay
    84704hCG free beta-chain test
    Salivary hormone testing for preterm labor riskHCPCSNot Covered
    S3652Saliva test, hormone level
    Initial blood type, Rh(D), and antibody status
    ScreeningDetermine blood type, Rh(D) status, and antibody status
    TimingDuring the first prenatal visit
    ReimbursementMay be reimbursable for all pregnant individuals
    Repeat Rh(D) antibody testing
    PopulationUnsensitized Rh(D)-negative individuals
    TimingRepeat testing at 24 to 28 weeks' gestation

    Submission and Reimbursement Requirements

    Documentation Required

    Submit Accurate Claims

    Submit accurate documentation of the services performed and use valid code combinations from HIPAA-approved code sets. Code claims appropriately according to applicable industry-standard coding guidelines, including CPT, HCPCS, ICD-10-CM, ICD-10-PCS, National Drug Codes, Uniform Billing, CMS National Correct Coding Initiative edits, and other CMS guidelines.

    Billing Rule

    Prepare for Claim Review

    Claims are subject to code-edit protocols and review based on benefit coverage terms, provider contract language, medical policies, reimbursement policies, and coding software logic. Submit additional documentation when requested.

    Screening and Eligibility Terms

    Anemia screening
    PurposeScreening for anemia
    Testing optionComplete blood count (CBC)
    Alternative testingHemoglobin and hematocrit with mean corpuscular volume
    Fetal fibronectin assay eligibility
    PatientPregnant individual
    Pregnancy typeSingleton or twin pregnancy
    Setting and presentationAmbulatory setting with signs or symptoms of preterm labor
    Policy Summary
    PayerBlue Cross Blue Shield - Illinois
    PolicyPrenatal Screening (Nongenetic)
    Policy CodePolicy RPLAB014
    Change TypeMaterial revision
    Effective DateDecember 4, 2026
    Next Review DateN/A
    Key ActionSubmit accurate documentation and valid code combinations using HIPAA-approved code sets and applicable industry coding guidelines.
    SourceLink
    On This Page
    Reimbursable Prenatal Screening ServicesCodes and Billing ParametersSubmission and Reimbursement RequirementsScreening and Eligibility Terms
    ExceptionUnless the biological father is known to be Rh(D)-negative
    Group B streptococcal screening
    FrequencyOnce per pregnancy
    Recommended timingGestational weeks 36 to 37
    ScreeningGroup B streptococcal disease
    Fetal fibronectin pregnancy type
    Pregnancy typeSingleton or twin pregnancy
    TestFetal fibronectin (FFN) assay
    ReimbursementMay be reimbursable when the stated eligibility conditions are met
    Fetal fibronectin setting and presentation
    SettingAmbulatory setting
    PresentationSigns or symptoms of preterm labor
    ReimbursementA fetal fibronectin assay may be reimbursable
    Note

    Product-Specific Requirements

    Lab management reimbursement criteria may vary by product. Review the applicable Plan documents to determine eligible coverage and product-specific requirements for services rendered.

    Note

    Fetal Fibronectin Eligibility

    A fetal fibronectin (FFN) assay may be reimbursable for an individual with a singleton or twin pregnancy who presents in an ambulatory setting with signs or symptoms of preterm labor.

    Denial Risk

    Nonreimbursable Testing

    Do not submit human chorionic gonadotropin (hCG) hormone testing for an individual with a normal pregnancy without complications. Salivary hormone testing to assess the risk of preterm labor is also not reimbursable.

    AssayFetal fibronectin (FFN) assay may be reimbursable